Innovative alternatives for metastatic CRPC after enzalutamide

Lancet Oncol. 2023 Jan;24(1):e9. doi: 10.1016/S1470-2045(22)00751-3.

Authors

Camilo A Medina¹, Cesar Diaz Ritter²

Affiliations

¹ Department of Urology, Fundación Santa Fe de Bogotá, Bogotá 110111, Colombia; Faculty of Medicine, Universidad de Los Andes, Bogotá, Colombia. Electronic address: camilo.medina@fsfb.org.co.
² Department of Urology, Fundación Santa Fe de Bogotá, Bogotá 110111, Colombia.

PMID: 36603932
DOI: 10.1016/S1470-2045(22)00751-3

No abstract available

Publication types

Letter
Comment

MeSH terms

Humans
Male
Nitriles
Phenylthiohydantoin / adverse effects
Prostatic Neoplasms, Castration-Resistant* / drug therapy
Prostatic Neoplasms, Castration-Resistant* / pathology
Receptors, Androgen

Substances

enzalutamide
Receptors, Androgen
Phenylthiohydantoin
Nitriles